MedTrace Logo

Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide

NCT01452854 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2022-07-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade Glioma (LGG). It is important to know if different patient factors and Temozolomide influence the rate of ovarian aging in women with LGG who have good long-term survival rates. This will allow better counseling about the effects of this particular chemotherapy agent on fertility in women.

Conditions

  • Low Grade Glioma

Sponsors & Collaborators

Principal Investigators

  • Mitchell Rosen, MD · UCSF Center for Reproductive Health and Fertility Preservation

  • Michael Prados, MD · UCSF Department of Neurological Surgery and Helen Diller Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01452854 on ClinicalTrials.gov